Cangene Corp. is a biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing products and technologies for global markets. It operates through two business segments: Biopharmaceutical Operations and Contract Services. The Biopharmaceutical Operations segment consists of sale of approved products and non specialty plasma, including specialty-plasma-derived products known collectively as hyperimmunes. The Contract Services segment includes revenues from the company's large government biodefense and commercial manufacturing contracts. The company was founded on February 22, 1984 and is headquartered in Winnipeg, Canada.